Merck & Co. Files Q1 2024 10-Q Report
Ticker: MRK · Form: 10-Q · Filed: 2024-05-03T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Merck's Q1 2024 10-Q is in. Check financials.
AI Summary
Merck & Co., Inc. filed its 10-Q for the period ending March 31, 2024. The company, headquartered in Kenilworth, NJ, operates in the pharmaceutical preparations industry. Key financial details and operational updates are provided in this quarterly report.
Why It Matters
This filing provides investors and analysts with the latest financial performance and operational details of Merck & Co., Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing (10-Q) and does not inherently present new risks.
Key Players & Entities
- Merck & Co., Inc. (company) — Filer of the 10-Q report
- 2000 GALLOPING HILL ROAD (location) — Business and mailing address of Merck & Co., Inc.
- Kenilworth, NJ (location) — City and State of Merck & Co., Inc.'s headquarters
- 2834 (industry_code) — Standard Industrial Classification code for Pharmaceutical Preparations
FAQ
What is the filing date of this 10-Q report?
The 10-Q report for Merck & Co., Inc. was filed on May 3, 2024.
What is the fiscal year end for Merck & Co., Inc.?
Merck & Co., Inc.'s fiscal year ends on December 31st.
What is the Standard Industrial Classification (SIC) code for Merck & Co., Inc.?
The SIC code for Merck & Co., Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the SEC file number for Merck & Co., Inc.?
The SEC file number for Merck & Co., Inc. is 001-06571.
What period does this 10-Q filing cover?
This 10-Q filing covers the first quarter of 2024, with the period of report ending on March 31, 2024.
From the Filing
0001628280-24-020283.txt : 20240503 0001628280-24-020283.hdr.sgml : 20240503 20240503161043 ACCESSION NUMBER: 0001628280-24-020283 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 24913161 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-Q 1 mrk-20240331.htm 10-Q mrk-20240331 FALSE 2024 Q1 0000310158 12/31 http://fasb.org/us-gaap/2023#LongTermDebtNoncurrent http://fasb.org/us-gaap/2023#LongTermDebtNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense 0000310158 2024-01-01 2024-03-31 0000310158 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000310158 mrk:A0.500Notesdue2024Member 2024-01-01 2024-03-31 0000310158 mrk:A1.875Notesdue2026Member 2024-01-01 2024-03-31 0000310158 mrk:A2.500Notesdue2034Member 2024-01-01 2024-03-31 0000310158 mrk:A1.375Notesdue2036Member 2024-01-01 2024-03-31 0000310158 2024-04-30 xbrli:shares iso4217:USD 0000310158 2023-01-01 2023-03-31 iso4217:USD xbrli:shares 0000310158 2024-03-31 0000310158 2023-12-31 0000310158 2022-12-31 0000310158 2023-03-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-03-01 2024-03-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-01-01 2024-03-31 0000310158 srt:ScenarioForecastMember mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember 2024-06-01 2024-07-31 0000310158 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember 2023-02-28 mrk:candidate 0000310158 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember 2023-03-31 0000310158 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember 2023-10-31 0000310158 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember 2023-01-01 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember 2023-01-01 2023-03-31 0000310158 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember mrk:OrganonCo.Member 2024-03-31 mrk:jurisdiction 0000310158 srt:MinimumMember mrk:Manufacturing